BioSenic provides third quarter 2024 Business Update

BioSenic provides third quarter 2024 Business UpdateBioSenic is actively seeking one or more new assets through a merger or acquisition process Mont-Saint-Guibert, Belgium, October 28, 2024, 7.00 am CEST – Regulated Information - BIOSENIC(Euronext Brussels and Paris: BIOS), theclinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, today provides its business update for the third quarter, ended 30 September 2024...

Mont-Saint-Guibert, 28/10/2024 (informazione.it - comunicati stampa - salute e benessere)

(Euronext Brussels and Paris: BIOS), the
clinical stage company specializing in serious autoimmune and inflammatory diseases, as well as cell repair, today provides its business update for the third quarter, ended 30 September 2024.

Unaudited numbers

.

investorrelations@biosenic.com

Attachment